Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clobetasol
Drug ID BADD_D00489
Description Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Indications and Usage Not Available
Marketing Status approved; experimental; investigational
ATC Code D07AD01
DrugBank ID DB11750
KEGG ID D07715
MeSH ID D002990
PubChem ID 5311051
TTD Drug ID D0FL5V
NDC Product Code Not Available
UNII ADN79D536H
Synonyms Clobetasol | Clofenazon | Clobetasol Propionate | Clobetasol 17-Propionate | Clobetasol 17 Propionate | Clobex | Cormax | OLUX | Dermovate | Embeline | Embeline E | Temovate
Chemical Information
Molecular Formula C22H28ClFO4
CAS Registry Number 25122-41-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lichenification23.03.08.010---
Miliaria23.02.03.014---
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Oedema08.01.07.006; 14.05.06.010---
Pain08.01.08.004--
Pain of skin23.03.03.003--
Paraesthesia17.02.06.005; 23.03.03.094--
Pharyngitis streptococcal11.02.06.002; 22.07.04.001---
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002---
Rash23.03.13.001---
Rash pustular11.01.12.002; 23.03.10.003--
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.014---
Skin atrophy23.01.05.001--
Skin disorder23.03.03.007---
Skin exfoliation23.03.07.003---
Skin fissures23.03.03.008---
Skin irritation23.03.04.009---
Skin striae23.01.05.002---
Telangiectasia23.06.03.001; 24.03.03.003--
Tenderness08.01.08.005---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urticaria10.01.06.001; 23.04.02.001--
Vision blurred06.02.06.007; 17.17.01.010--
Application site dryness08.02.01.011; 12.07.01.011; 23.03.03.024---
Skin tightness23.03.03.018---
Asteatosis23.02.07.006---
Application site discolouration08.02.01.030; 12.07.01.030; 23.03.03.023---
Induration08.01.03.020---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages